HealthPrize Technologies, the leading cloud-based patient experience and
adherence platform for life science companies, today announced the
launch of Drive, a new product to streamline the development and
management of return on investment (ROI)-driven patient adherence
programs for medications to treat chronic disease. Based on hundreds of
millions of patient interactions in programs built for pharmaceutical
brands across a broad range of drugs, diseases, demographics and
delivery methods, Drive applies HealthPrize’s proven approach of
gamification, behavioral economics and loyalty marketing to improve
patient adherence to their prescribed medications.
“HealthPrize has developed unique expertise in changing patient behavior
at scale through the patient engagement, education and adherence
programs we have developed for our pharmaceutical clients,” said Tom
Kottler, CEO and co-founder of HealthPrize. “Drive, the result of our
years of experience, simplifies and optimizes the pharmaceutical
industry’s development of adherence programs targeted at improving
patient outcomes, reducing total cost of care and generating new
revenue.”
Drive enables pharmaceutical marketers to easily and effectively build a
branded or unbranded adherence program configured to their medications’
unique requirements, patient challenges and business needs in just a few
months. Based on technology proven to improve adherence by an average of
52% over a brand’s baseline rate, programs built using Drive are
configured to deliver significant ROI for pharmaceutical brands in both
primary and specialty diseases.
“Drive is a combination of tactics and product features that have
evolved from studying and responding to the behaviors of the more than
one million patients who have engaged with the HealthPrize platform,”
said John Ragland, chief product officer, HealthPrize. “This product
brings together these established components to develop patient
experiences proven to lift adherence and deliver measurable new revenue
for our clients’ brands.”
Advanced capabilities in programs built with Drive include:
-
Personalized content journey and actionable behavioral
triggers configured to the product’s dosing schedule, patient
challenges and business goals -
Robust messaging segmentation based on patient attributes such as
therapy experience level, insurance type or demographics -
Interactive program performance dashboards, enhanced data capture and
analysis capabilities -
Full integration with co-pay savings card and other third-party data
suppliers -
Self-service targeted survey capabilities to gather deep patient
insights
Drive is available in three tiers to provide pricing and service option
flexibility for pharmaceutical brands of all sizes, from specialty
medications for rare diseases to medications for broad-reaching primary
care conditions. The product can support multiple brands and languages,
and is fully HIPAA compliant and HITRUST certified.
-
Drive Essentials: Streamlined adherence programs for pharmaceutical
brands -
Drive Complete: Robust adherence programs for single or multiple
brands and languages, deployable across the enterprise, across the
globe -
Drive Insights: Powerful tools to create qualitative patient datasets
and unlock deep patient insights
Learn more online at www.healthprize.com/drive.
About HealthPrize Technologies
HealthPrize Technologies enables pharmaceutical marketers to develop
powerful branded and unbranded adherence programs that engage, educate
and motivate patients to start and stay on their medications. Our
platform powers and advances adherence across all drugs, diseases,
demographics and delivery methods. Learn more at www.healthprize.com
or on Twitter at @HealthPrize.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190416005292/en/